IMUX — Immunic Inc
NASDAQ · Healthcare · Biotechnology
$15.00
+$0.42 (+2.88%)
Immunic Inc (IMUX) is a biotechnology company listed on NASDAQ. It is led by Daniel Vitt Ph.D., based in 1200 Avenue of the Americas, New York, NY, United States, 10036, with about 90 employees. Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Net income was -$25.6M. IMUX currently screens at market cap $79.5M.
Use this IMUX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IMUX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IMUX SEC filings page. Lician reads the product cache first so this HTML stays unique to Immunic Inc even when a live quote feed is slow.
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
IMUX Key Statistics
Market Cap
$79.45M
Volume
177,734
Previous Close
$16.46
Day Range
$16.15 – $17.18
EPS
-$1.00
Revenue
$0.00
Net Income
-$100.51M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
90
IMUX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$100.51M | -$93.61M | -$120.41M | -$21.18M |
| EPS (Diluted) | -$1.00 | -$2.11 | -$3.78 | -$0.81 |
Total Assets
$40.87M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$35.67M
Operating Cash Flow
-$84.77M
Free Cash Flow
$0.00
Immunic Inc Company Information
- CEO & Director
- Daniel Vitt Ph.D.
- Headquarters
- 1200 Avenue of the Americas, New York, NY, United States, 10036
- Website
- imux.com
- Phone
- 332 255 9818
- IPO / Founded
- 2014-04-17
- Sector
- Healthcare
- Industry
- Biotechnology